SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ayeyou who wrote (24596)6/1/2014 10:53:28 PM
From: ogi1 Recommendation

Recommended By
stonecrop

  Read Replies (1) of 49086
 
Photofrin brought to commercialization by Canadian Co. QLT with cancer applications, bladder cancer being one of them but main thrust was Macular degeneration in the eye, that was 1989-1995. Not up to speed on all the company changes since then.QLT Was a market darling for quite a while. At that time laser light could only penetrate 1 cm, limiting the possible response to the PDC drug by depth of target. The new TLT therapeutic laser has achieved 10 CM Light penetration and recent results indicate their PDC is far more active than the current FDA approved PDCs

Theralase PDC was found to be 668,000 times more effective than ALA and 198 times more effective than Photofrin, two currently approved FDA photoactive drugs."

After 25 years it makes sense that we may be seeing progress in the development of PDCs
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext